Literature DB >> 30961980

Time in therapeutic range and risk of thromboembolism and bleeding in patients with a mechanical heart valve prosthesis.

Eva Havers-Borgersen1, Jawad H Butt2, Naja E Vinding2, Christian Torp-Pedersen3, Gunnar Gislason4, Lars Køber2, Emil L Fosbøl2.   

Abstract

OBJECTIVE: Oral anticoagulation with vitamin K antagonists is recommended after mechanical heart valve replacement. However, data regarding the association between the quality of vitamin K antagonist treatment and the risk of complications are sparse.
METHODS: Patients undergoing mechanical heart valve replacement (1997-2012) with available data on international normalized ratio values were identified in Danish registries. The quality of vitamin K antagonist treatment between discharge after valve replacement and 6 months postdischarge (ie, index) was assessed as time in therapeutic range (TTR) ≥70% or <70% reflecting the percentage of time in therapeutic international normalized ratio interval. Patients were followed from index until occurrence of an outcome of interest (ie, thromboembolism and bleeding), death, or end of study (December 31, 2012), whichever came first. The risk of outcomes according to quality of vitamin K antagonist treatment was estimated with multivariable Cox regression.
RESULTS: In total, 659 patients undergoing mechanical heart valve replacement were included in the study. Median number of international normalized ratio measurements in the 6-month period after surgery was 13 (interquartile range, 8-19). Median TTR was 54.9% (interquartile range, 39.0%-72.9%) and 29.1% of patients had a TTR ≥70%. Median follow-up was 6.1 years. The risk of thromboembolism was significantly lower in the group with TTR ≥70% compared with TTR <70% (hazard ratio, 0.44; 95% confidence interval, 0.22-0.85), whereas no significant difference concerning risk of bleeding among groups was found (hazard ratio, 0.63; 95% confidence interval 0.36-1.08).
CONCLUSIONS: In patients undergoing mechanical heart valve replacement, TTR <70% in the 6-month period after surgery was associated with an increased risk of thromboembolic events but not bleeding compared with TTR ≥70%.
Copyright © 2019 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Nordic Medico-Statistical Committee; epidemiology; mechanical heart valve prostheses; oral anticoagulation; time in therapeutic range; vitamin K antagonists

Year:  2019        PMID: 30961980     DOI: 10.1016/j.jtcvs.2019.02.061

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  4 in total

1.  Long-term Outcomes Following Mechanical or Bioprosthetic Aortic Valve Replacement in Young Women.

Authors:  Sabin J Bozso; Abigail White; Jimmy J H Kang; Yongzhe Hong; Colleen M Norris; Olivia Lakey; Roderick G G MacArthur; Jayan Nagendran; Jeevan Nagendran; Michael C Moon
Journal:  CJC Open       Date:  2020-06-30

2.  Outcomes of tissue versus mechanical aortic valve replacement in patients 50 to 70 years of age.

Authors:  Lauren V Huckaby; Ibrahim Sultan; Thomas G Gleason; Shangzhen Chen; Floyd Thoma; Forozan Navid; Arman Kilic
Journal:  J Card Surg       Date:  2020-07-11       Impact factor: 1.778

3.  Case report: Mechanical mitral prosthetic valve thrombosis in the context of COVID-19 despite effective anticoagulation.

Authors:  Clarisse Jeckelmann; Bojan Djokic; Valérie Duchatelle; Grégoire Girod
Journal:  Eur Heart J Case Rep       Date:  2022-01-24

4.  Outcomes related to anticoagulation management for mechanical valve replacements.

Authors:  Lauren V Huckaby; Laura M Seese; Thomas G Gleason; Ibrahim Sultan; Yisi Wang; Floyd Thoma; Arman Kilic
Journal:  J Thorac Dis       Date:  2021-05       Impact factor: 2.895

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.